Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 17/20 | 0.72 |
| ▸ | DRD2 | P14416 | 16/20 | 0.72 |
| ▸ | DRD3 | P35462 | 14/20 | 0.72 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.54 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5003814 | 0.98 | DRD4 (0.70) | DRD4DRD2DRD3TAAR1CARM1 | |
| Hydrochloric Acid SCHEMBL8042255 | 0.82 | DRD4 (0.97) | DRD4DRD2DRD3TAAR1 | |
| SCHEMBL1249273 | 0.82 | MAOB (0.53) | DRD4DRD2DRD3ALDH1A1 | |
| SCHEMBL16964935 | 0.81 | DRD4 (0.70) | DRD4DRD2DRD3CARM1ALDH1A1 | |
| SCHEMBL10576211 | 0.81 | DRD4 (0.81) | DRD4DRD2DRD3TAAR1 | |
| Hydrochloric Acid SCHEMBL8055046 | 0.81 | DRD4 (0.97) | DRD4DRD2DRD3TAAR1 | |
| Hydrochloric Acid SCHEMBL8055016 | 0.81 | DRD4 (0.97) | DRD4DRD2DRD3 | |
| Hydrochloric Acid SCHEMBL8057879 | 0.81 | DRD4 (0.97) | DRD4DRD2DRD3TAAR1ALDH1A1 | |
| SCHEMBL4028552 | 0.80 | ALDH3A1 (0.53) | DRD4DRD2DRD3ALDH1A1 | |
| Hydrochloric Acid SCHEMBL1534353 | 0.80 | MAOB (0.55) | DRD4DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7414063-B2 | Inhibitors of Akt (protein kinase B) | ELI LILLY AND COMPANY (US) | 2008-08-19 | — | — | US | disclosed |
| US-20070043040-A1 | Inhibitors of akt (protein kinase b) | ELI LILLY AND COMPANY | 2007-02-22 | — | — | US | disclosed |
| EP-1611105-A1 | ISOQUINOLINE-5-SULFONIC ACID AMIDES AS INHIBITORS OF AKT (PROTEIN KINASE B) | ELI LILLY AND COMPANY (US) | 2006-01-04 | — | — | EP | disclosed |
| WO-2004094386-A1 | ISOQUINOLINE-5-SULFONIC ACID AMIDES AS INHIBITORS OF AKT (PROTEIN KINASE B) | ELI LILLY AND COMPANY (US) | 2004-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043040-A1 | Inhibitors of akt (protein kinase b) | AKT1, AKT2, BRAF | DRD4 4862/4885DRD2 4867/4885DRD3 4873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.